Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Lee Schwartzberg MD, FACP

Lee S. Schwartzberg MD, FACP

Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, Nevada

Dr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.

In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.

Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.

Disclosures

  • Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
  • Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer

Recent Contributions to PracticeUpdate:

  1. 2024 Top Story in Oncology: Triplet Therapy for HR+/HER2− Metastatic Breast Cancer
  2. Next-Generation Oral SERD Camizestrant vs Fulvestrant in Postmenopausal ER+/HER2− Advanced Breast Cancer
  3. Ipatasertib Plus Paclitaxel for PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic TNBC
  4. ASCO 2024: Abstract Recommendations From Dr. Lee Schwartzberg for Breast Cancer
  5. Outcomes of Fulvestrant, Palbociclib, and Avelumab Treatment After Progression on CDK4/6i and Aromatase Inhibitor Therapy for HR+/HER2− Metastatic Breast Cancer
  6. 2023 Top Story in Metastatic Breast Cancer: Capivasertib—The First of a New Class of Agents to Treat Certain Patients With Metastatic Breast Cancer
  7. ESMO 2023: Recommendations From Dr. Lee Schwartzberg for Breast Cancer
  8. Outcomes of Neratinib + Fulvestrant + Trastuzumab and Biomarker Analysis in Patients With HR+/HER2−, HER2-Mutant MBC
  9. CDK4/6 Inhibitors for Hormone-Receptor-Positive (HR+), HER2-Negative (HER2-) Advanced Breast Cancer (ABC)
  10. Toripalimab With nab-Paclitaxel (nab-P) for Metastatic or Recurrent Triple-Negative Breast Cancer

Elsewhere

Most Read This Week

Recently Updated